|
|
|
100+ participants
8 health agency speakers
21 sessions over 3 days
65% industry participation
28 hours total duration
7 hours networking time
› Request 2009 brochure
|
Conference:
Pre-conference workshop
8 December 9am - 5pm
Day 1
9 December 8am - 5.30pm
Day 2
10 December 8am - 5.30pm
Post-conference workshop
11 December 9am - 5pm
Venue: Royal Garden Hotel, London, United Kingdom
|
|
|
|
Meet our speakers
Health Technology Assessment Analyst, Diabetes, Obesity and Devices, Novo Nordisk Consultant Cardiologist, Barnet General Hospital Head EU level activities on Health Technology Assessment, European Commission Director, Coordinating Secretariat for EUnetHTA, National Board of Health Head of Health Technology Assessment Policy and Development and Account Management, Pfizer, Inc. Director, Agency for Healthcare Research and Quality Senior Policy Advisor, College voor Zorgverzekeringen Director, Market Access and Public Affairs, EMEA, Shire Human Genetic Therapies Dr Pietro Folino Gallo, Head of Unit, OSMED Co-ordination Unit, Italian Medicines Agency (AIFA) Head of Department, Monitoring & Health Technology Assessment, National Board of Health Health Economist / Founder, BaseCase Alastair Kent, Director, Genetic Interest Group Senior Vice President, Chief Medical Officer, Blue Cross Blue Shield Association Dr Zbigniew Krol, Formerly, Deputy Director for Health Technology Assessment, Agency for Health Technology Assessment - AHTAPol Global Health Economics & Outcomes Research, Head Business Unit Cardiovascular, Bayer Schering Pharma AG Chief Executive Officer, Vision Healthcare Consultancy Chief Executive, Myeloma UK Co-founding partner formerly Director Health Technology Assessment, Amgen, Stratas Partners AG Director Health Technology Assessment Division, Haute Autorit� de Sant� Head of Methods Department, Gemeinsamer Bundesausschuss Vice President Corporate Relations, GlaxoSmithKline President & Chief Executive Officer, Canadian Agency for Drugs and Technologies in Health (CADTH) Senior Director Health Economics & Outcomes Research, AstraZeneca Pharmaceuticals (Pty ) Ltd South Africa
|
|
|
Meindert Boysen
Associate Director Single Technology Appraisals
NICE
 Dr François Meyer Director, Health Technology Assessment Division
Haute Autorité de
Santé
 Dr Allan Korn Senior Vice President, Chief Medical Officer
BlueCross BlueShield Association
 Jerome Boehm Head EU level activities on HTA
European Commission
 Dr Matthias Perleth Head of Methods Department
Gemeinsamer Bundesausschuss
|
|
|
|
|
